返回
В
В. В. Волков
healthcare institution "brest regional oncology dispensary"
24H指数
200论文数
7.2K被引数
收录论文 19
发表时间
Corrigendum to “Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial” [Eur J Cancer. 227 (2025) 115674]勘误:“低剂量抗CTLA-4(Nurulimab)联合抗PD-1(Prolgolimab)对比抗PD-1单药治疗晚期皮肤黑色素瘤的临床结局改善:OCTAVA III期试验结果”[Eur J Cancer. 227 (2025) 115674]

